Whole Brain Radiotherapy (WBRT)

RADIATION3 trials

Sponsors

Sanofi, Memorial Sloan Kettering Cancer Center, Juergen Debus

Conditions

Brain MetastasesBrain Metastases, AdultBreast CancerNon-small Cell Lung Cancer (NSCLC)

Phase 1

Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

TerminatedNCT00807170

SanofiNon-small Cell Lung Cancer (NSCLC)

Start: 2009-05-31End: 2010-08-31Updated: 2016-08-29

Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)

CompletedNCT01724606

Memorial Sloan Kettering Cancer CenterBrain Metastases, Breast Cancer

Start: 2012-11-05End: 2022-03-01Updated: 2022-03-07

Phase 2

Stereotactic Radiotherapy of the Resection Cavity of Brain Metastases vs. Post-operative Whole-brain Radiotherapy

CompletedNCT03285932

Juergen DebusBrain Metastases, Adult

Start: 2018-02-01End: 2021-07-08Updated: 2022-11-03

Related Papers

A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.

2021-06-109 citations

MLTI-02. A PHASE I TRIAL OF SORAFENIB WITH WHOLE BRAIN RADIOTHERAPY (WBRT) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES AND A CORRELATIVE FLT-PET BRAIN IMAGING STUDY IN PATIENTS RECEIVING WBRT +/- SORAFENIB

Neuro-Oncology Advances2019-08-01

Abstract P1-19-03: A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging in patients receiving WBRT with or without sorafenib

Cancer Research2019-02-15

A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging to evaluate treatment response after WBRT sorafenib.

Journal of Clinical Oncology2014-05-201 citations